BRIEF published on 05/08/2024 at 12:35, 2 years 1 month ago Résultats Positifs pour l'Essai Phase 3 SOLARIS sur l’Olanzapine Schizophrénie Medincell TEV-‘749 SOLARIS Olanzapine
BRIEF published on 05/08/2024 at 12:35, 2 years 1 month ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years 1 month ago Informations privilégiées / Autres communiqués Les résultats positifs de l'étude de phase 3 SOLARIS démontrent l'efficacité de TV-749, injection sous-cutanée mensuelle pour la schizophrénie par Teva et Medincell Santé Mentale Schizophrénie Medincell TV-749 Teva
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years 1 month ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
BRIEF published on 05/08/2024 at 09:05, 2 years 1 month ago Medincell Temporarily Suspends its Euronext Paris Listing Euronext Paris Press Release Financial Markets Medincell Share Suspension
BRIEF published on 05/08/2024 at 09:05, 2 years 1 month ago Medincell suspend temporairement sa cotation sur Euronext Paris Euronext Paris Marchés Financiers Communiqué De Presse Médine Partager La Suspension
PRESS RELEASE published on 05/08/2024 at 09:00, 2 years 1 month ago Inside Information / Other news releases Medincell suspends listing of shares on Euronext Paris pending press release. Innovative biopharmaceutical company developing long-acting injectable drugs Euronext Paris Biopharmaceutical Suspension Medincell Long-acting Injectable Drugs
PRESS RELEASE published on 05/08/2024 at 09:00, 2 years 1 month ago Informations privilégiées / Autres communiqués Medincell suspend la cotation de ses actions sur Euronext Paris, en attente de la publication d'un communiqué. Reprise des négociations prévue demain Euronext Paris Cotation Suspension Medincell Communiqué
Published on 06/27/2026 at 16:50, 14 hours 9 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 5 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 6 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 7 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 8 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 6 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 6 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 7 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 7 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 7 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
